Compare Elastic NV (ESTC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Twist Bioscience Corp — how do they compare? Elastic NV trades at $95.26 (market cap $9.77B), while Twist Bioscience Corp trades at $157 (market cap $10.32B). The key difference: Elastic NV and Twist Bioscience Corp are close in size by market cap, and Elastic NV is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Twist Bioscience Corp for 27 Days on average.
| ESTC | TWST | |
|---|---|---|
Market Cap | $9.77B | $10.32B |
Volume | 945,514 | 5,894,998 |
Sector | Technology | Health |
52-Week High | $99.91 | $205.00 |
52-Week Low | $43.30 | $25.45 |
Typical Hold Time | 10 Days | 27 Days |
Enterprise Value | $8.91B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $93.1, down 1.59% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust revenue growth, improving profitability into 2026, and positive sentiment from analysts, with 22 buy ratings and no sells. Recent product launches, including AI-driven metrics and serverless vector database offerings, highlight innovation in its observability and search platforms.
The stock presents a growth opportunity driven by product innovation and expanding profit margins, but risks include high valuation multiples and competitive pressures in the enterprise software sector. Analyst consensus targets $79.50, below the current price, suggesting cautious optimism amid execution risks and market volatility.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
